Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of zimberelimab versus investigator's choice chemotherapy in relapsed or refractory classical Hodgkin lymphoma
CTR20222153Phase 3Active
- Sponsor
- WuXi Biologics
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zimberelimab in classical Hodgkin lymphoma (cHL), sponsored by WuXi Biologics. Started Aug 2022; status: active.
02
Drugs
zimberelimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20222153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222153.